Phase I/II Study of CAR.70- Engineered IL15-transduced Cord Blood-derived NK Cells in Conjunction With Lymphodepleting Chemotherapy for the Management of Relapse/Refractory Hematological Malignances
M.D. Anderson Cancer Center
M.D. Anderson Cancer Center
Massachusetts General Hospital
St. Jude Children's Research Hospital
Fred Hutchinson Cancer Center
Ossium Health, Inc.
M.D. Anderson Cancer Center
Masonic Cancer Center, University of Minnesota
Center for International Blood and Marrow Transplant Research
Mayo Clinic
M.D. Anderson Cancer Center
H. Lee Moffitt Cancer Center and Research Institute
City of Hope Medical Center
Case Comprehensive Cancer Center
University of Arizona
M.D. Anderson Cancer Center
Thomas Jefferson University
Thomas Jefferson University
Incyte Corporation
University of Wisconsin, Madison
National Institutes of Health Clinical Center (CC)
City of Hope Medical Center
Massachusetts General Hospital
Barbara Ann Karmanos Cancer Institute
University of Rochester
Masonic Cancer Center, University of Minnesota
University of Florida
City of Hope Medical Center
City of Hope Medical Center
Fred Hutchinson Cancer Center
Case Comprehensive Cancer Center
Thomas Jefferson University
Masonic Cancer Center, University of Minnesota
Thomas Jefferson University
Memorial Sloan Kettering Cancer Center
Memorial Sloan Kettering Cancer Center
City of Hope Medical Center
Instituto Nacional de Cancer, Brazil
Ohio State University Comprehensive Cancer Center
National Cancer Institute (NCI)
Therapeutic Advances in Childhood Leukemia Consortium
Advice Pharma Group srl
Astellas Pharma Inc
Roswell Park Cancer Institute
University College, London
OHSU Knight Cancer Institute
Beth Israel Deaconess Medical Center
Washington University School of Medicine
University of Nebraska
University of Nebraska
M.D. Anderson Cancer Center